Systematic evaluation of the induction of efficient neutralizing antibodies by recombinant multicomponent subunit vaccines against monkeypox virus

Vaccine, Год журнала: 2024, Номер 42(26), С. 126384 - 126384

Опубликована: Сен. 24, 2024

Язык: Английский

---

The Impact of COVID-19 on RNA Therapeutics: A Surge in Lipid Nanoparticles and Alternative Delivery Systems

Pharmaceutics, Год журнала: 2024, Номер 16(11), С. 1366 - 1366

Опубликована: Окт. 25, 2024

The COVID-19 pandemic has significantly accelerated progress in RNA-based therapeutics, particularly through the successful development and global rollout of mRNA vaccines. This review delves into transformative impact on RNA with a strong focus lipid nanoparticles (LNPs) as pivotal delivery platform. LNPs have proven to be critical enhancing stability, bioavailability, targeted mRNA, facilitating unprecedented success vaccines like those developed by Pfizer-BioNTech Moderna. Beyond vaccines, LNP technology is being explored for broader therapeutic applications, including treatments cancer, rare genetic disorders, infectious diseases. also discusses emerging systems, such polymeric viral vectors, which offer alternative strategies overcome existing challenges related immune responses, tissue-specific targeting. Additionally, we examine pandemic's influence regulatory processes, fast-tracked approvals therapies, surge research funding that spurred further innovation field. Public acceptance grown, laying groundwork future developments personalized medicine. By providing an in-depth analysis these advancements, this highlights long-term evolution therapeutics precision drug technologies.

Язык: Английский

---

DNA tetrahedron nanoparticles service as a help carrier and adjvant of mRNA vaccine

Journal of Translational Medicine, Год журнала: 2024, Номер 22(1)

Опубликована: Ноя. 14, 2024

To investigate the potential of DNA nanoparticles (DNPs) as carriers and adjuvants for mRNA vaccines. Customized oligonucleotides were assembled into tetrahedra (DNA-TH), which subsequently complexed with streptavidin encoding green fluorescent protein (GFP). Various assays conducted to evaluat stability DNPs, their cellular uptake, immune activation potential, GFP transcription efficiency. P53-mutant HSC-3 cells used establish a subcutaneous xenograft tumor model explore effects DNPs in disease model. The remained stable extracellularly rapidly taken up by antigen-presenting cells. Compared naked mRNA, statistically significantly activated responses facilitated expression both vitro vivo. Immunization DNP-GFP complexes induced higher antibody titers compared mRNA. demonstrated good biocompatibility. DNP-p53 inhibited growth tumors mice p53-mutant cells, outperforming p53 blank control groups, significant difference (P < 0.05). show promise improving vaccine delivery efficacy. Further optimization these could lead highly effective broad applications.

Язык: Английский

---

RNA Vaccines: Yeast as a Novel Antigen Vehicle

Опубликована: Апрель 26, 2023

In the last decades, technological advances related to RNA manipulation enabled and expanded its application in vaccine development. This approach comprises synthetic single-stranded mRNA molecules that direct translation of antigen responsible for activating desired immune response. The success vaccines depends on delivery vehicle employed. Among systems, yeasts emerge as a new natural platform. presence β-glucans mannans wall is adjuvant action this system. Yeasts are already employed deliver protein antigens, with efficacy demonstrated through pre-clinical clinical trials. Yeast β-glucan capsules, microparticles, nanoparticles capable modulating host responses have high capacity carry small molecules, bioavailability upon oral immunization targeting receptors present anti-gen-presenting cells (APCs). Besides, interesting vehicles protection specific therapeutic based shRNA or dsRNA. review, we an overview attributes yeast derivatives RNA-based vaccines, discussing their current challenges prospects using promising strategy.

Язык: Английский

---

PEGylated Dmoc phosphoramidites for sensitive oligodeoxynucleotide synthesis

Organic & Biomolecular Chemistry, Год журнала: 2023, Номер 21(45), С. 9005 - 9010

Опубликована: Янв. 1, 2023

Using PEGylated Dmoc (pDmoc) phosphoramidites for oligodeoxynucleotide (ODN) synthesis increases the solubility of ODN on solid support and enables longer sensitive ODNs.

Язык: Английский

---

Role of size, surface charge, and PEGylated lipids of lipid nanoparticles (LNPs) on intramuscular delivery of mRNA

Research Square (Research Square), Год журнала: 2024, Номер unknown

Опубликована: Июль 31, 2024

Background Lipid nanoparticles (LNPs) are currently the most commonly used non-viral gene delivery system. Their physiochemical attributes, encompassing size, charge and surface modifications, significantly affect their behaviors both in vivo vitro. Nevertheless, effects of these properties on transfection distribution LNPs after intramuscular injection remain elusive. In this study, with varying sizes, lipid-based charges PEGylated lipids were formulated to study distribution. Luciferase mRNA (mLuc) was loaded in as a model nucleic acid. Results In vitro results indicated that smaller-sized those neutral potential presented superior efficiency injection. Surprisingly, sizes did not exert notable influence LNPs. Furthermore, shorter acyl chains contributed enhanced due cellular uptake lysosomal escape capabilities. Notably, mechanisms underlying differed among containing various types lipids, which primarily attributed length chain. Conclusions Together, insights underscore pivotal role nanoparticle characteristics route. This only fills crucial knowledge gaps but also provides invaluable directions for effective via

Язык: Английский

---

PLGA Nanoparticles Coated with Activated Dendritic Cell Membrane Can Prolong Protein Expression and Improve the Efficacy of mRNA

Advanced Therapeutics, Год журнала: 2024, Номер unknown

Опубликована: Авг. 6, 2024

Abstract In future, mRNA drugs likely play crucial roles in vaccines and protein replacement therapy etc. Lipid nanoparticles (LNPs) are the only formulation approved for delivery. However, cancer vaccine, encapsulated LNP can encode limited (20–40) tumor antigens. Due to highly heterogeneous of cells antigens, including more diverse antigens could improve efficacy vaccines. Including both strong immunogenic maximize Herein, poly (lactic‐co‐glycolic acid) (PLGA) activated dendritic cell membrane were designed as delivery platforms, which possess merits such prolonged expression, lyophilized formulation, greater Dendritic with particles loading whole activate broad range antigen‐specific T cells. The sustained release PLGA significantly prolong expression APCs, lyophilization improved stability formulation. Compared LNPs, these nanovaccines therapeutic mRNA. addition, mice treated was than that LNPs. Overall, a new platform delivering demonstrated, have better efficacy.

Язык: Английский

---

Synthesis of cell penetrating peptide sterol coupler and its liposome study on S-mRNA

European Journal of Medicinal Chemistry, Год журнала: 2023, Номер 261, С. 115822 - 115822

Опубликована: Сен. 16, 2023

Язык: Английский

---